Press Releases

FirstWave Bio to Initiate Phase 2a/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19

Proprietary formulation of approved antiviral medicine targets viral “reservoir” in the gut believed responsible for prolonged…

Your browser is out of date!

Update your browser to view this website correctly. Update my browser now